Onset dynamics of type A botulinum neurotoxin-induced paralysis

Experimental studies have demonstrated that botulinum neurotoxin serotype A (BoNT/A) causes flaccid paralysis by a multi-step mechanism. Following its binding to specific receptors at peripheral cholinergic nerve endings, BoNT/A is internalized by receptor-mediated endocytosis. Subsequently its zinc-dependent catalytic domain translocates into the neuroplasm where it cleaves a vesicle-docking protein, SNAP-25, to block neurally evoked cholinergic neurotransmission. We tested the hypothesis that mathematical models having a minimal number of reactions and reactants can simulate published data concerning the onset of paralysis of skeletal muscles induced by BoNT/A at the isolated rat neuromuscular junction (NMJ) and in other systems. Experimental data from several laboratories were simulated with two different models that were represented by sets of coupled, first-order differential equations. In this study, the 3-step sequential model developed by Simpson (J Pharmacol Exp Ther 212:16–21,1980) was used to estimate upper limits of the times during which anti-toxins and other impermeable inhibitors of BoNT/A can exert an effect. The experimentally determined binding reaction rate was verified to be consistent with published estimates for the rate constants for BoNT/A binding to and dissociating from its receptors. Because this 3-step model was not designed to reproduce temporal changes in paralysis with different toxin concentrations, a new BoNT/A species and rate (kS) were added at the beginning of the reaction sequence to create a 4-step scheme. This unbound initial species is transformed at a rate determined by kS to a free species that is capable of binding. By systematically adjusting the values of kS, the 4-step model simulated the rapid decline in NMJ function (kS ≥0.01), the less rapid onset of paralysis in mice following i.m. injections (kS = 0.001), and the slow onset of the therapeutic effects of BoNT/A (kS < 0.001) in man. This minimal modeling approach was not only verified by simulating experimental results, it helped to quantitatively define the time available for an inhibitor to have some effect (tinhib) and the relation between this time and the rate of paralysis onset. The 4-step model predicted that as the rate of paralysis becomes slower, the estimated upper limits of (tinhib) for impermeable inhibitors become longer. More generally, this modeling approach may be useful in studying the kinetics of other toxins or viruses that invade host cells by similar mechanisms, e.g., receptor-mediated endocytosis.

[1]  J. Keller Recovery from botulinum neurotoxin poisoning in vivo , 2006, Neuroscience.

[2]  F. Lebeda,et al.  Membrane Channel activity and Translocation of Tetanus and Botulinum Neurotoxins , 1999 .

[3]  R. S. Williams,et al.  Localization of sites for 125I-labelled botulinum neurotoxin at murine neuromuscular junction and its binding to rat brain synaptosomes. , 1982, Toxicon : official journal of the International Society on Toxinology.

[4]  L. Simpson Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. , 1980, The Journal of pharmacology and experimental therapeutics.

[5]  M. Geeves Kinetics of fast enzyme reactions: Theory and practice , 1980 .

[6]  C. Permpikul,et al.  An outbreak of botulism in Thailand: clinical manifestations and management of severe respiratory failure. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Richard D. O'Brien,et al.  The Receptors : a comprehensive treatise , 1979 .

[8]  Eric A. Johnson,et al.  SV2 Is the Protein Receptor for Botulinum Neurotoxin A , 2006, Science.

[9]  J. Dolly,et al.  Productive and non‐productive binding of botulinum neurotoxin A to motor nerve endings are distinguished by its heavy chain , 1996, Journal of neuroscience research.

[10]  J. Romano,et al.  Chemical Warfare Agents : Toxicity at Low Levels , 2000 .

[11]  Philip K. Russell,et al.  Botulinum toxin as a biological weapon: medical and public health management. , 2001, JAMA.

[12]  B. Davletov,et al.  The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves , 2006, FEBS Letters.

[13]  F. Lebeda,et al.  Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations. , 1995, Toxicon : official journal of the International Society on Toxinology.

[14]  L. Simpson,et al.  Identification of the major steps in botulinum toxin action. , 2004, Annual review of pharmacology and toxicology.

[15]  C. Schengrund,et al.  Correlation of cleavage of SNAP-25 with muscle function in a rat model of Botulinum neurotoxin type A induced paralysis. , 2001, Toxicon : official journal of the International Society on Toxinology.

[16]  G. Oyler,et al.  Pharmacological Countermeasures for Botulinum Intoxication , 2000 .

[17]  E. Albuquerque,et al.  Kinetic analysis of end plate currents altered by atropine and scopolamine. , 1978, Molecular pharmacology.

[18]  Hiroaki Kitano,et al.  Next generation simulation tools: the Systems Biology Workbench and BioSPICE integration. , 2003, Omics : a journal of integrative biology.

[19]  J. McLauchlin,et al.  An outbreak of serious illness and death among injecting drug users in England during 2000. , 2002, Journal of medical microbiology.

[20]  D. Dressler,et al.  Botulinum Toxin: Mechanisms of Action , 2005, European Neurology.

[21]  T. Lohman,et al.  Review of Wyman and Gill, Binding and Linkage: Functional Chemistry of Biological Macromolecules , 1993 .

[22]  J. Dolly,et al.  Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation , 2003, Molecular and Cellular Neuroscience.

[23]  J. Marks Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization , 2004, Movement disorders : official journal of the Movement Disorder Society.

[24]  L. Simpson Studies on the binding of botulinum toxin type A to the rat phrenic nerve-hemidiaphragm preparation. , 1974, Neuropharmacology.

[25]  C. Millard,et al.  Medical Defense Against Protein Toxin Weapons , 2005 .

[26]  G. Schiavo,et al.  Neurotoxins affecting neuroexocytosis. , 2000, Physiological reviews.

[27]  K. Bostian,et al.  Endoproteinase Activity of Type A Botulinum Neurotoxin: Substrate Requirements and Activation by Serum Albumin , 1997, Journal of protein chemistry.

[28]  P. Savino,et al.  Botulinum toxin therapy. , 1991, Neurologic clinics.

[29]  C. Schengrund,et al.  Botulinum neurotoxin A changes conformation upon binding to ganglioside GT1b. , 2004, Biochemistry.

[30]  E. Otten Chemical Warfare Agents: Toxicity at Low Levels , 2002 .

[31]  J. Hablitz,et al.  Role of uptake inγ-aminobutyric acid (GABA)-mediated responses in guinea pig hippocampal neurons , 1985, Cellular and Molecular Neurobiology.

[32]  S. Joshi,et al.  An Initial Assessment of the Systemic Pharmacokinetics of Botulinum Toxin , 2006, Journal of Pharmacology and Experimental Therapeutics.

[33]  K. Roger Aoki Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. , 2002, Toxicon : official journal of the International Society on Toxinology.

[34]  D. Truong Botulinum Toxin Therapy , 1991, The Western journal of medicine.

[35]  D. Rodbard,et al.  Kinetics of Cooperative Binding , 1979 .

[36]  K. Aoki Botulinum toxin: a successful therapeutic protein. , 2004, Current medicinal chemistry.

[37]  H. Gutfreund,et al.  Enzyme kinetics , 1975, Nature.

[38]  Eric A. Johnson,et al.  Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective. , 2001, Toxicon : official journal of the International Society on Toxinology.

[39]  J. Coffield,et al.  Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc. , 2001, The Journal of pharmacology and experimental therapeutics.

[40]  M. Montal,et al.  Translocation of botulinum neurotoxin light chain protease through the heavy chain channel , 2003, Nature Structural Biology.

[41]  H. Bigalke,et al.  The HCC‐domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction , 2003, Molecular microbiology.

[42]  C. Frassoni,et al.  Entering neurons: botulinum toxins and synaptic vesicle recycling , 2006, EMBO reports.